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Perioperative concentrations of serum troponin I (TnI) in the ﬁrst 72h after TAVI were
measured for detection of myocardial injury.
Results: CVR (ﬁg. 1) was impaired at baseline (1.590.37) improved after BAV and
subsequent valve implantation (1.680.37). Recovery time towards bAPV was longer
after the rapid pacing (RP) period during valve implantation than after RP period
during BAV (12.9416.57s vs. 7.969.67s; p¼0.322). A positive correlation was
found between the duration of RP and AUC for perioperative troponin I (p< 0.05).HR
95,0% CI for
Exp(B)
p-valueLower Upper
Gender 1.063 0.678 1.667 0.789
Ejection fraction <40% 1.964 1.118 3.450 0.019
COPD 1.241 0.683 2.255 0.479
Acute MI (<90 days,%) 1.807 1.051 3.106 0.032
Critical perioperative State 2.495 0.875 7.112 0.087
Pulmonary Hypertension 1.520 0.962 2.401 0.073
Renal failure (Creatinine 2.2 mg/dl, %) 2.958 1.591 5.500 0.001
Coronary artery disease 1.040 0.657 1.645 0.868
Previous CABG (%) 1.030 0.566 1.876 0.922
Previous valve surgery 2.297 0.983 5.366 0.055
Diabetes 1.269 0.843 1.911 0.254
Valve type (CoreValve/Sapien) 1.285 0.788 2.096 0.314
New-onset LBBB 1.765 1.160 2.684 0.008Conclusions: TAVI leads to an improvement in CVR,which may pathophysiologi-
cally contribute to attenuation of ischemic symptoms,and a longer RP duration
appears to be associated with myocardial injury.
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Background: The SAPIEN 3 transcatheter heart valve (THV) and its low proﬁle
delivery system (Edwards Lifesciences, CA) incorporate features intended to facilitate
accurate positioning and improve paravalvular sealing.
Methods: A multicenter evaluation of patients implanted with SAPIEN 3 valves was
utilized for this speciﬁc analysis. Optimal pre implantation device position was
deﬁned as position of the lower border of the central marker at the lower border of the
aortic cusps with  1.5mm (i.e.  half central marker length). Implantation images
were evaluated by a dedicated core lab blinded to clinical results.
Results: A total of 143 patients implanted with SAPIEN 3 were included in the study:
56.4% male, age 82.17.7 years, STS score 12.110.1%. Baseline aortic valve area
0.730.26 cm2. All implantations were successful (76.2% transfemoral access),
without malposition or implantation of a second device. Paravalvular regurgitation
was < mild in 95.8%. The rate of major vascular complication was 3.5% and acute
kidney injury 1.4% (VARC 2). At 30 days mortality was 1.4% and major stroke
1.4%. Positioning was optimal in 62 patients and suboptimal in 81. Pre-implantation
depth (lower border of central marker below the line of the cusp border) was
1.062.41mm: 0.20.8mm in cases with optimal position, 3.11.41mm in low-
position and -3.191.36 in those with high-position (p< 0.001). Patients with optimal
device positioning had a lower pacemaker rate than patients with a suboptimal
position (3.2% vs. 18.5%, p¼0.007) and although device size was similar, post im-
plantation aortic valve area was larger (25.92.2mm vs. 25.92.0mm, p¼0.95, and
1.910.49cm2 vs. 1.630.47cm2, p¼0.04, respectively).
Conclusions: This multicenter evaluation suggests that SAPIEN 3 implantation is
associated with excellent results. Clinical outcomes are further improved with optimal
device positioning, according to study deﬁnition.
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therapy in the treatment of the severe aortic stenosis. Compared with surgical aortic
valve replacement, transcatheter aortic valve implantation (TAVI) is associated with a
higher risk of developing a new conduction disorder that necessitates permanent
pacemaker implantation (PM). The most frequently observed conduction disorder is
left bundle branch block (LBBB). The aim of this study was to establish the predicting
factors of the mid-term all-cause mortality, highlighting the importance of a new-onset
LBBB.
Methods: This study included a total of 634 patients who underwent TAVI with the
Medtronic CoreValve (n¼112) and the Edwards SAPIEN Valve (n¼512) between
May 2008 and April 2012. The effect of demographic parameters and treatment modes
on overall survival were assessed using regression analysis models.
Results: Multivariate regression analyses revealed, that persistent new-onset LBBB
was an independent predictor of all-cause mortality in the one-year follow up (hazard
ratio [HR] 1.77, 95% conﬁdence interval [CI]: 1.16-2.68; p ¼ 0.008). Other inde-
pendent predictors were: renal failure (HR: 2.96, 95% CI: 1.59-5.50; p ¼ 0.001), a left
ventricular ejection fraction of < 40% (HR: 1.96, 95% CI: 1.12-3.45; p ¼ 0.019),
and acute myocardial infarction within 90 days prior to TAVI (HR: 1.81, 95% CI:
1.05-3.11; p ¼ 0.032).Conclusions: This study demonstrated that persistent new-onset LBBB was an in-
dependent predictor of all-cause mortality at the end of the ﬁrst year, along with renal
failure, poor left ventricular ejection fraction and acute myocardial infarction within
90 days prior to TAVI.
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Background: Whether patients with reduced left ventricular function present worse
outcome after transcatheter aortic valve implantation (TAVI) is controversial. The aim
of this study was assess the impact of baseline severe impairment of left ventricular
function on mortality after TAVI.
Methods: Six-hundred-forty-nine patients with aortic stenosis underwent TAVI with
the CoreValve system (92.8%) or the Edwards SAPIEN valve system (7.2%). Base-
line LVEF was measured by the echocardiographic Simpson method. The impact of
LVEF30% on mortality was assessed by Cox regression.
Results: Patients with LVEF 30% (N¼63), as compared to those with LVEF > 30%
(N¼586), had a higher prevalence of NHYA class >2 (p< 0.001) and presented with
a higher Euroscore (p< 0.001). Procedural success was similar in both groups (98.4%
vs 97.2%, p¼1). After a median follow-up of 436 days, all-cause mortality (23.8% vs
23.7%, p¼0.87, HR 0.96, 95% CI 0.56-1.63) and cardiac mortality (19.1% vs 17.6%,
p¼0.89, HR 1.04, 95% CI 0.57-1.90) were similar in patients with LVEF 30% aslvular disease - Aortic: TAVR B211
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cant different between the two groups (11.1% vs 6.3%, p¼0.14, HR 1.81, 95% CI
0.81-4.06). Patients with LVEF 30% had a trend toward higher risk of 30-day
cardiac mortality (11.1% vs 5.3%, p¼0.06, HR 2.16, 95% CI 0.95-4.90), which
disappeared after multivariable adjustment (p¼0.22). In a prespeciﬁed subgroup
analysis restricted to patients with LVEF30%, patients with baseline mean trans-
valvular gradient < 40 mmHG (low-gradient) presented a non-signiﬁcant higher risk
of all-cause death (31.6% vs 12.0%, p¼0.14, HR 2.46, 95% CI 0.69-8.74) and of
cardiac death (23.7% vs 12.0%, p¼0.32, HR 1.90, 95% CI 0.51-7.03) as compared to
patients with mean transvalvular gradient 40 mmHg (high-gradient).
Conclusions: Baseline severe impairment of LVEF is not a predictor of increased
short-term and mid-term mortality after TAVI. Among patients with severe
impairment of left ventricular function, those with low transvalvular gradient
deserve a careful evaluation because of numerically higher mortality rates. Selected
patients with severe impairment of left ventricular function should not be denied
TAVI.
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Background: Aortic valve implantation without balloon predilation may facilitate the
procedure, reduce rapid pacing duration and may impact the stroke rate. For the self-
expandable CoreValve this strategy has been shown to be feasible and safe in small
studies. Whether direct aortic valve implantation is applicable to the balloon-
expandable Edwards SAPIEN 3 valve is unknown. is applicable to the balloon-
expandable Edwards SAPIEN 3 valve is unknown. The aim of the present study was
to evaluate the feasablity and safety of transfemoral implantion of the Edwards SA-
PIEN 3 aortic valve without balloon predilation.
Methods: Forty one consecutive patients with severe symptomatic aortic stenosis and
high surgical risk were prospectively enrolled to receive the Edwards SAPIEN 3 aortic
valve without predilation.
Results: Mean age of the patients was 83.2  5.9 years, 58 % were male. Successful
implantation without predilation was achieved in 95.1 % of patients. In 2 patients (4.8
%) the prosthesis could not cross the native aortic valve due to severe asymmetric
calciﬁcation and an aortic valve oriﬁce area (AOA) of 0.4 and 0.5 cm2, respectively.
After predilation was performed from the contralateral site, the valve could be suc-
cessfully implanted in both patients. Post-dilation was performed in one patient due to
moderate aortic regurgitation. The cardiovascular 30 day MACCE rate was 2.4 %,
total mortality was 9,7% , reasons for death were pneumonia (1pt), urosepsis (1pt),
and subarachnoidal bleeding (1pt).
Conclusions: Transfemoral implantation of the Edwards SAPIEN 3 aortic valve
without balloon predilation is feasable and safe in the majority of patients, limitations
are severe asymmetric valve calciﬁcation in combination with AOA of 0.5 cm2 or
less.
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Background: Reducing length of stay (LoS) in selected TAVR patients is both
safe and feasible, but its role in mitigating healthcare costs has not been fully
evaluated.
Methods: Using the Medicare Provider Analysis and Review File, we retrospectively
analyzed 4,464 Medicare patients who underwent transfemoral-TAVR and were
discharged alive in ﬁscal year 2012. Hospitalization cost and discharge disposition
were assessed for 5 LoS cohorts (Table 1). Multivariate regression modeling, based on
patient demographics, comorbidities, and complications, was used to derive anB212 JACC Vol 64/11/Suppl B j Sepadjusted mean cost for each cohort. The 2013 MedPAR ﬁles, available shortly, will
also be analyzed and incorporated prior to presentation.
Results: The unadjusted mean hospitalization cost of transfemoral-TAVR cases was
$61,130 and the mean LoS was 7.7 days. Compared to patients with a LoS of 6-7
days, short-stay patients (discharged on day 1-3) had an unadjusted cost difference of
-$8,216 (p< 0.0001) and an adjusted difference of -$6,036 (p< 0.0001). Importantly,
patients discharged earlier were less likely to require assistance at discharge (65% vs
42%, p< 0.0001). Temporal trends between 2012 and 2013 will also be analyzed.
Conclusions: Early discharge in selected patients can have meaningful cost savings at
a program level. Additionally, patients discharged early require less post-acute care
services than patients with longer stays, alleviating concerns that early discharge of
Medicare patients may be associated with higher societal costs. Efforts aimed at
optimized patient selection and peri-TAVR care with a view to reducing LoS are
warranted.
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Background: TAVI has gained signiﬁcant relevance in the treatment of inoperable or
high-risk patients with symptomatic aortic stenosis. Several risk scores have been
proposed to estimate the perioperative and long-term risk of patients undergoing
TAVI. However, assessment of individual risk remains difﬁcult. We thus aimed to
analyze whether biomarkers may improve risk stratiﬁcation.
Methods: We prospectively included 267 patients undergoing TAVI (using balloon-
expandable Edwards Sapien XT prostheses) at our institution from Feb. 2011 until
Dec. 2013. n¼260 patients were available for complete follow up. 56.2% were fe-
males, mean age was 81.9 years ( 6.8 years), 57.3% were treated via transfemoral,
28.1% transapical, 14.6% transaortic access. Biomarkers (hsTNT and NTproBNP) as
well as other parameters were measured a day before TAVI, 3 and 7 days post-pro-
cedure. 11.2% had severely reduced EF, and mean log. Euroscore (ES) was 26.3% (
17%). Median follow-up was 262 days (IQR 77-501d), the primary endpoint was
survival time; a total of 74 deaths (27.7%) occurred. 30d mortality was 6.0%. All
possible prognostic factors were analyzed by Cox regression analysis with backward
selection based on the likelihood ratio criteria.
Results: Median preprocedural hsTNT values were 28.4 pg/ml (IQR 16.2-46.1 pg/
ml). From all potential prognostic factors, preprocedural hsTNT (HR¼2.67 for upper
quartile vs. quartiles 1-3, CI 1.63-4.38, p< 0.001) and the log. ES (HR¼1.98, CI 1.2-
3.27 p¼0.006) emerged as independent prognostic parameters for adverse outcome. In
contrast, unimpaired renal function appeared to be protective (HR¼0.48, CI: 0.21-
1.06, p¼0.047). In addition, we also tested whether the VARC-2 cut-off for
myocardial damage (hsTNT peak value exceeding 15 as the upper reference limit,
210 pg/ml) was of prognostic relevance. At 72 h post-TAVI, n¼87 pts (37.5%) had
hsTNT levels 210 pg/ml. However, these pts did not reveal a signiﬁcant difference
in survival compared to pts with a hsTNT < 210 pg/ml at this timepoint.
Conclusions: In conclusion, elevated preprocedural hsTNT is an independent risk
predictor of all-cause death while periprocedural hsTNT elevation failed to exhibit
prognostic relevance.
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Background: The impact of preoperative mitral regurgitation on clinical outcome of
patients undergoing TAVI is controversial. This study is to assess the contribution of
mitral regurgitation to clinical outcomes after TAVI.
Methods: Data from Asian TAVI multicenter registry were pooled and analyzed. In
total, 185 patients with severe symptomatic aortic stenosis undergoing TAVI were
included. 16 patients (8.6%) had preoperative mitral regurgitation  moderate and the
study patients were divided into 2 groups according to preoperative mitral regurgi-
tation: group I (mitral regurgitation  mild) and group II (  moderate).
Results: Baseline LVEF and aortic valve area were smaller in Group II, but there were
no difference in other demographics including age, sex, diabetes, hypertension, pre-
vious PCI, previous CABG, peripheral artery disease, mean pressure gradient and
Logistic EuroSCORE. There was no difference in device success rate (79.7% vs.
81.3%; p > 0.99), however 30-day mortality was higher in group II (30-day mortality:
1.5% vs. 18.8%; Relative Risk, 12.53; 95% conﬁdence interval [CI], 2.31 – 98.84;tember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
